Levicept: a novel biological for the treatment of chronic pain Levicept is a biopharmaceutical company focused solely on the preclinical and clinical development of p75NTR-Fc as treatment for osteoarthritis and chronic pain.
Levicepts lead molecule p75NTR-Fc was originally discovered at Pfizer by Levicepts founder and CEO, Simon Westbrook, who subsequently acquired the asset following the closure of Pfizers research site in Sep 2013.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/levicept-ltd” connections=”true” suffix=””]
In 2014, Levicept raised £10 Mn in Series A financing from Advent Life Sciences, Gilde Healthcare and Index Ventures. In addition, it was awarded a £2.4 Mn grant from the Biocatalyst Fund of the UKs innovation agency, Innovate UK, in April 2014.
Recover your password.
A password will be e-mailed to you.